Clinical Trial

Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A clinical study to explore the safety, efficacy and cell metabolic kinetics of universal CD19/20 car-t cell injection in moderate to severe refractory systemic lupus erythematosus. This study is a single arm, open, exploratory dose increasing clinical study, which aims to evaluate the safety, efficacy and cell metabolic dynamics of ct1192 cells in patients with SLE.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-12.
Status change: Not Yet Recruiting → Recruiting 2025-11-18
Trial Details
NCT Number NCT07031713
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators: CARsgen Therapeutics Co., Ltd.
Conditions Systemic Lupus Erythematosus (SLE)
Enrollment 12 participants
Start Date 2025-07-11
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-24